New Insights on Rilpivirine Resistance

Nonnucleoside reverse transcriptase inhibitors (NNRTI) are popular components of combination antiretroviral therapy. Until 2006, the NNRTI family had only two drugs in Europe (efavirenz and nevirapine) and another (delavirdine) in North America. Despite their proven efficacy, the clinical use of first-generation NNRTI has been limited by side effects, low barrier to resistance, and broad cross-resistance.